HOME >> BIOLOGY >> NEWS
Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus

Presented at Amer. Assoc. for the Study of Liver Diseases Conference

BOULDER, Colorado, November 9, 1998 -- Ribozyme Pharmaceuticals, Inc. (RPI) (Nasdaq: RZYM) today announced that HEPTAZYME®, a ribozyme designed to selectively destroy Hepatitis C Virus (HCV) RNA, was effective in decreasing Hepatitis C Viral RNA in cell culture assays. This work was presented at the American Association for the Study of Liver Diseases (AASLD) conference in Chicago by Dr. Lawrence Blatt, RPI's Senior Director of Biopharmacology and Preclinical Research. In these studies, HEPTAZYME® demonstrated significant inhibition of the HCV viral translation process in cells at very low doses, and in a manner that implies applicability across multiple forms of the virus.

Hepatitis C Virus (HCV) is the most common chronic bloodborne infection in the United States today. A recent Centers for Disease Control report stated that over 4 million Americans are chronically infected with HCV, and it is estimated that 500 million people are infected with HCV worldwide. The disease, which is more common than HIV, kills 8,000-10,000 Americans annually, and the death toll is expected to triple over the next 10-20 years. Furthermore, development of effective treatments has been hampered by the presence of multiple forms of HCV, with at least six genotypes and more than 90 subtypes known.

HEPTAZYME® contains many novel features believed to be important for HCV treatment. First, HEPTAZYME® is a ribozyme, a catalytic RNA molecule that has the unique potential to bind and cleave HCV RNA specifically and selectively, thus suggesting that viral replication can be inhibited without affecting other normal physiological processes. Next, HEPTAZYME® cleaves the HCV RNA at a location that is completely conserved in all known genotypes and subtypes of HCV, which gives HEPTAZYME® the potential to inhibit all forms of the virus. Finally, since HCV replicates in the cytoplas
'"/>

Contact: Neil Cohen
neil@noonanrusso.com
415-677-4455 x. 205
Noonan/Russo Communications
9-Nov-1998


Page: 1 2 3

Related biology news :

1. Ribozyme package effective against hepatitis B virus
2. Ribozymes Come Ready For Action
3. Ribozymes To The Rescue: New UF Gene Therapy Shows Promise For Treatment Of Inherited Blindness
4. Interdisciplinary Method Offers New Way To Study Ribozymes
5. Vion Demonstrates Readiness Of First Tumor-Targeting Salmonella For Human Testing Against Solid Tumors
6. Engineering Animation, Inc. Demonstrates Internet Anatomy At Visible Human Project Conference
7. Study Demonstrates High Conservation Potential Of Logged Rainforest
8. Potential for enhanced sequestration of carbon in soils supports evaluations
9. Potent toxin reveals new antibiotic resistance mechanism
10. Potential blood test for colon cancer risk
11. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2019)... ... 2019 , ... MMJ International Holdings, the premier medical cannabis ... trials and research, announced that it is seeking fast track designation approval from ... the review and approval of drugs in development that treat serious or life ...
(Date:2/11/2019)... ... February 11, 2019 , ... ... services, announced a new forensic genealogy service offering to law enforcement investigators and ... testing and genealogy to develop ancestral relationships between samples and deliver leads to ...
(Date:2/6/2019)... ... February 05, 2019 , ... Amino Labs, ... partnered with MindFuel, a leading organization in educational science, technology, engineering and math ... Labs has pioneered a syn-bio starter kit for teachers – the Amino ...
Breaking Biology News(10 mins):
(Date:2/14/2019)... N.J. (PRWEB) , ... February 14, 2019 , ... ... provider of helium based leak testing systems for the pharmaceutical, biotechnology and food ... the company moving forward. Brian Mulhall has been named Chief Executive ...
(Date:2/6/2019)... ... February 05, 2019 , ... Firmex ... executive management team to acquire Firmex, one of the fastest-growing and most widely-used ... Montreal-based private equity firm. Debt financing was provided by the Bank of Montreal. ...
(Date:2/2/2019)... POMONA, Calif. (PRWEB) , ... January 31, 2019 , ... ... in food sciences as it hosts the Nuriv 2019 Expo West Music and Tech ... With a mission to foster innovation in the natural foods, beverages, and dietary supplement ...
(Date:2/2/2019)... NANTES, France (PRWEB) , ... February 01, 2019 ... ... technologies, is pleased to announce the appointment of its new CEO, Julien Dert, ... has 25 years of international experience in finance and management, in which more ...
Breaking Biology Technology:
Cached News: